APTX - アプティニクス (Aptinyx Inc.) アプティニクス

 APTXのチャート


 APTXの企業情報

symbol APTx
会社名 Aptinyx Inc (アプティニクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including depression neuropathic pain migraine traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925 a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc develops AGN-241751 for major depressive disorder indications.   アプティニクスは米国のバイオ医薬品企業。臨床段階で、脳や神経系疾患の治療に対する新規かつ独自の合成小分子の開発・商業化に従事する。同社パイプラインには、糖尿病による末梢神経障害や線維筋痛向けのNYX-2925、外傷後ストレス障害向けのNYX-783、パ―キンソン病認識機能障害向けのNYX-458を含む。本社所在地はイリノイ州エバンストン。   Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate-rather than block or over-activate-NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson's disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders.
本社所在地 909 Davis Street Suite 600 Evanston IL 60201 USA
代表者氏名 Norbert G. Riedel ノーベルト・G・リーデル
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 847-871-0377
設立年月日 42156
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数
url www.aptinyx.com
nasdaq_url https://www.nasdaq.com/symbol/aptx
adr_tso
EBITDA EBITDA(百万ドル) -40.34500
終値(lastsale) 26.41
時価総額(marketcap) 884635275.84
時価総額 時価総額(百万ドル) 917.46160
売上高 売上高(百万ドル) 6.98100
企業価値(EV) 企業価値(EV)(百万ドル) 738.37160
当期純利益 当期純利益(百万ドル) -40.37900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aptinyx Inc revenues increased 78% to $4.6M. Net loss increased 50% to $25M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 53% to $25.5M (expense) General and administrative increase of 43% to $3.2M (expense).

 APTXのテクニカル分析


 APTXのニュース

   Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022  2022/04/27 11:47:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022 at 5:00 p.m. ET to report first quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial (844) 200-6205 (domestic) or (929) 526-1599 (i
   Expert Ratings for Aptinyx  2022/04/21 14:05:58 Benzinga
Within the last quarter, Aptinyx (NASDAQ: APTX ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 2 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Aptinyx has an average price target of $4.0 with a high of $5.00 and a low of $2.00. Below is a summary of how these 4 analysts rated Aptinyx over the past 3 months. The greater the number of bullish ratings, … Full story available on Benzinga.com
   Mid-Morning Market Update: Markets Mixed; US Jobless Claims Fall Last Week  2022/04/07 13:40:38 Benzinga
U.S. stocks traded mixed this morning, with the Dow Jones dropping around 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.43% to 34,349.60 while the NASDAQ rose 0.37% to 13,940.29. The S&P also fell, dropping, 0.08% to 4,477.39. Also check this: Alphabet And 3 Other Stocks Sold By Insiders Top Headline US initial jobless claims fell by 5 thousand to 166 thousand in the week ended April 2nd. However, analysts were expecting a reading of 200 thousand. Equities Trading UP Momentus Inc. (NASDAQ: MNTS ) shares shot up 31% to $3.87 as the company signed multiple launch agreements with Space Exploration Technologies Corp. (SpaceX), a Tesla CEO Elon Musk-led company. Shares of System1, Inc. (NYSE: SST ) got a boost, shooting 26% to $25.16. The company on Monday reported Q4 and FY22 financials results. Origin Agritech Limited (NASDAQ: SEED ) shares were also up, gaining 25% to $9.12 after the company announced it has signed purchase agreements to sell two feedstock companies a total 50,000 metric tons of its corn for RMB150 million.
   Aptinyx Shares Tank On Disappointed Data From Mid-Stage Diabetic Peripheral Neuropathy Study  2022/04/07 13:22:43 Benzinga
Aptinyx Inc (NASDAQ: APTX ) shares are plunging after results from a Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy (DPN). NYX-2925 did not achieve statistically significant separation from placebo on the study''s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale (NRS) during week 12. "We continue to believe, however, … Full story available on Benzinga.com
   Aptinyx''s stock falls 48% after drug fails in Phase 2b trial  2022/04/07 12:44:41 MarketWatch
Shares of Aptinyx Inc. tumbled 48.7% in premarket trading on Thursday after the company said an experimental treatment for painful diabetic peripheral neuropathy failed to meet the primary endpoint in a Phase 2b clinical trial. "The data from this study do not currently point to a path forward in development for painful DPN," Aptinyx CEO Andy Kidd said in a news release. The company said it is still evaluating the therapy as a treatment for fibromyalgia, and data is expected from a Phase 2b study in the third quarter of this year. Aptinyx''s stock is down 12.3% this year, while the S&P 500 had declined 5.0%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
   Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference  2021/08/31 11:57:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Monday, September 13, 2021. A l
   The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck  2021/08/19 11:37:27 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV ) Alkermes plc (NASDAQ: ALKS ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Gilead Sciences, Inc. (NASDAQ: GILD ) GlaxoSmithKline plc (NYSE: GSK ) ( announced FDA approval for label expansion for its Jemperli) Novo Nordisk A/S (NYSE: NVO ) Innoviva, Inc. (NASDAQ: INVA ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ) Omega Therapeutics, Inc. (NASDAQ: OMGA ) (IPOed July 30) Pfizer, Inc. (NYSE: PFE ) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) ResMed Inc. (NYSE: RMD ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 18) Absci Corporation (NASDAQ: ABSI ) Achieve Life Sciences, Inc. (NASDAQ: ACHV ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) ADMA Biologics, Inc. (NASDAQ: ADMA ) Akouos, Inc. (NASDAQ: AKUS ) Angion Biomedica Corp. (NASDAQ: ANGN ) Aptinyx Inc. (NASDAQ: APTX ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) AVROBIO, Inc. (NASDAQ: AVRO ) Axsome Therapeutics, Inc. (NASDAQ: AXSM ) Biomea Fusion, Inc. (NASDAQ: BMEA ) BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV ) Catalyst Biosciences, Inc. (NASDAQ: CBIO ) Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI ) Chemomab Therapeutics Ltd. (NASDAQ: CMMB ) CNS Pharmaceuticals, Inc. (NASDAQ: CNSP ) Compass Therapeutics, Inc. (OTC: CMPX ) ContraFect Corporation (NASDAQ: CFRX ) CymaBay Therapeutics, Inc. (NASDAQ: CBAY ) CytomX Therapeutics, Inc. (NASDAQ: CTMX ) Epizyme,
   Aptinyx Inc. (APTX) Q2 2021 Earnings Call Transcript  2021/08/11 07:01:35 The Motley Fool
APTX earnings call for the period ending June 30, 2021.
   Aptinyx Inc. (APTX) CEO Norbert Riedel on Q2 2021 Results - Earnings Call Transcript  2021/08/11 02:49:07 Seeking Alpha
   Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights  2021/08/10 20:10:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the second quarter of 2021 and provided key business updates. We continue to make good progress in advancing our pipeline programs to enable multiple important Phase 2 data readouts in 2022, said Norbert Riedel, PhD, chief executive officer of Aptinyx. With several trans
   Aptinyx to Participate in Upcoming Investor Conferences  2021/06/17 11:57:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the Company will be participating in two upcoming investor conferences: Oppenheimer Biotech by the Lake 2021 Investor Summit Norbert Riedel, Ph.D., chief executive officer, will participate in the Hot Topics in Neurological Disorder Therapeutics and Technologies Panel discussion on Tue
   Aptinyx Provides Updates On Mid-Stage NYX-783 Program In PTSD Patients  2021/06/16 10:45:55 Benzinga
After a Type C meeting with the FDA, Aptinyx Inc (NASDAQ: APTX ) has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD). The program will consist of two separate studies to evaluate NYX-783 at two dose levels: 50 mg (Study 1) and 150 mg (Study 2). Both the studies will have 300 patients each. Study Full story available on Benzinga.com
   Aptinyx updates on mid-stage clinical program for PTSD therapy  2021/06/15 20:31:35 Seeking Alpha
   Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder  2021/06/15 20:10:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that it has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD) after having received the minutes from its recent Type C meeting with the U.S. Food and Drug Administration (FDA). The company expects to initiate the Phase 2b program in
   Stock is blowing up- Aptinyx Inc. (NASDAQ:APTX) encountered the change of 13.03%  2021/06/10 21:55:36 Stock Equity
On Thursday, Shares of Aptinyx Inc. (NASDAQ:APTX) reached at $3.21 price level during last trade its distance from 20 days simple moving average was 23.82%, and its distance from 50 The post Stock is blowing up- Aptinyx Inc. (NASDAQ:APTX) encountered the change of 13.03% appeared first on Stocks Equity .

 関連キーワード  (医薬品 米国株 アプティニクス APTX Aptinyx Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)